TEANECK, N.J. / Aug 14, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time.
Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884.
A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit https://investors.pahc.com.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.
| Last Trade: | US$20.49 |
| Daily Change: | -1.57 -7.12 |
| Daily Volume: | 285,864 |
| Market Cap: | US$416.770M |
January 23, 2025 August 28, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
